Patent US3871809A successfully refreshed from Google Patents.
Patent US2841399A successfully refreshed from Google Patents.
Patent US4640834A successfully refreshed from Google Patents.
US4640834A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inactivating reproducible filterable pathogens in blood products as well as a method of producing blood products
Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1985-02-26
•
Granted: 1987-02-03
•
Expires: 2005-02-26
Abstract
Abstract A method of inactivating viruses in blood products is described, wherein the blood products are heat-treated in a humid or in a solid state in the presence of inorganic or organic hydroxyl group-containing compounds having an H+-dissociation constant of <10-11 in a concentration of more than 0.05 (5% by weight) and less than 0.70 (70% by weight). The hydroxyl group-containing compounds may be water, methanol, ethanol or mannitol. The temperature may amount up to 121 DEG C., the heat treatment may last from 1 s to 100 h. The inactivation method may be applied for producing blood products selected from enzymes, proenzymes including coagulation factors, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin or plasma, the inactivation destroying any reproducible filterable pathogens that might be present.
Inventors
- 👤 Johann Eibl
- 👤 Otto Schwarz
- 👤 Fritz Elsinger
- 👤 Gunter Wober
- 👤 Anton Philapitsch
- 👤 Yendra Linnau
- 👤 Friedrich Dorner
- 👤 Karl Trambauer
- 👤 Wolfgang Frechinger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 10:48
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61L; A61L2/00; A61L2/02; A61L2/04; A61L2103/00; A61L2103/05
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
129 words
A method of inactivating viable filterable pathogens in a blood product, which comprises: placing said blood product in a solid state in a closeable treating zone in the presence of a hydroxyl group-containing compound selected from the group consisting of water, methanol, ethanol, and mixtures thereof, and closing said treating zone; maintaining the content of said hydroxyl group-containing compound in said treating zone to provide said blood product with a content of hydroxyl group-containing compounds of more than 0.05 (5% by weight) and less than 0.70 (70% by weight); and heating said blood product in the solid state in the closed treating zone at a temperature of between 50° and 121° C. to increase the partial vapor pressure of said hydroxyl group-containing compound, to thereby inactivate viable filterable pathogens.
Claim 2
Independent Claim
129 words
A method of inactivating viable filterable pathogens in a blood product, which comprises: placing said blood product in a solid state in a closeable treating zone in the presence of a hydroxyl group-containing compound selected from the group consisting of water, methanol, ethanol, and mixtures thereof, and closing said treating zone; maintaining the content of said hydroxyl group-containing compound in said treating zone to provide said blood product with a content of hydroxyl group-containing compounds of more than 0.05 (5% by weight) and less than 0.70 (70% by weight); and heating said blood product in the solid state in the closed treating zone at a temperature of between 50° and 121° C. to increase the partial vapor pressure of said hydroxyl group-containing compound, to thereby inactivate viable filterable pathogens.
Claim 3
Dependent Claim
44 words
A method as set forth in claim 1, wherein the content of said hydroxyl group-containing compound is maintained to provide said blood product with a content of hydroxyl group-containing compound of more than 0.05 (5% by weight) and less than 0.40 (40% by weight).
Claim 4
Dependent Claim
49 words
A method as set forth in claim 2, wherein said hydroxyl group-containing compound is water, said water being present in the blood product at between about 0.06 (6% by weight) and about 0.30 (30% by weight), and said heating being at a temperature of from 50° to 90° C.
Claim 5
Dependent Claim
24 words
A method as set forth in claim 1, wherein said blood product is heated in the presence of an inert gas free of oxygen.
Claim 6
Dependent Claim
21 words
A method as set forth in claim 4, wherein said blood product is heated in the presence of an oxygen-binding substance.
Claim 7
Dependent Claim
15 words
A method as set forth in claim 4, wherein said inert protective gas is nitrogen.
Claim 8
Dependent Claim
29 words
A method as set forth in claim 1, wherein the content of said hydroxyl group-containing compound is maintained by the addition of a hydroxyl group-containing compound in gaseous form.
Claim 9
Dependent Claim
23 words
A method as set forth in claim 7, wherein said content of said hydroxyl group-containing compound is less than 0.40 (40% by weight).
Claim 10
Dependent Claim
16 words
A method as set forth in claim 7, wherein said hydroxyl group-containing compound is water vapor.
Claim 11
Dependent Claim
28 words
A method as set forth in claim 9, wherein the partial vapor pressure of said hydroxyl group-containing compound is increased to between about 0.1 and about 2 bars.
Claim 12
Dependent Claim
16 words
A method as set forth in claim 1, wherein said viable filterable pathogens are hepatitis viruses.
Claim 13
Dependent Claim
23 words
A method as set forth in claim 1, wherein said viable filterable pathogens are agents capable of transmitting AIDS (acquired immune deficiency syndrome).
Claim 14
Dependent Claim
24 words
A method as set forth in claim 1, wherein said blood product is heated for a period of from 1 s to 100 h.
Claim 15
Dependent Claim
49 words
A method of producing blood products selected from the group consisting of enzymes, proenzymes, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin and plasma and mixtures thereof by using a method as set forth in claim 1, wherein said inactivation is effected at any desired stage of said product method.
Claim 16
Dependent Claim
23 words
A method as set forth in claim 14, further comprising converting said blood products into a galenic or pharmaceutical preparation after said inactivation.
Claim 17
Dependent Claim
27 words
A method as set forth in claim 1, further comprising additional fractionation steps for liberating said heat-inactivated blood products from any neoproteins or neoantigens formed during heat-inactivation.
Claim 18
Dependent Claim
158 words
A blood product, selected from the group consisting of enzymes, proenzymes, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin and plasma, produced by fractionation, wherein the blood product has been treated, at any desired stage of the fractionation, by a method which comprises: placing said blood product in a solid state in a closeable treating zone in the presence of a hydroxyl group-containing compound selected from the group consisting of water, methanol, ethanol, and mixtures thereof, and closing said treating zone; maintaining the content of said hydroxyl group-containing compound in said treating zone to provide said blood product with a content of hydroxyl group-containing compound of more than 0.05 (5% by weight) and less than 0.70 (70% by weight); and heating said blood product in the solid state in the closed treating zone at a temperature of between 50° and 121° C. to increase the partial vapor pressure of said hydroxyl group-containing compound, to thereby inactivate viable filterable pathogens.
Claim 19
Dependent Claim
158 words
A blood product, selected from the group consisting of enzymes, proenzymes, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin and plasma, produced by fractionation, wherein the blood product has been treated, at any desired stage of the fractionation, by a method which comprises: placing said blood product in a solid state in a closeable treating zone in the presence of a hydroxyl group-containing compound selected from the group consisting of water, methanol, ethanol, and mixtures thereof, and closing said treating zone; maintaining the content of said hydroxyl group-containing compound in said treating zone to provide said blood product with a content of hydroxyl group-containing compound of more than 0.05 (5% by weight) and less than 0.70 (70% by weight); and heating said blood product in the solid state in the closed treating zone at a temperature of between 50° and 121° C. to increase the partial vapor pressure of said hydroxyl group-containing compound, to thereby inactivate viable filterable pathogens.
Claim 20
Dependent Claim
14 words
A composition comprising the blood product of claim 17 in a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
158 words
A blood product, selected from the group consisting of enzymes, proenzymes, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin and plasma, produced by fractionation, wherein the blood product has been treated, at any desired stage of the fractionation, by a method which comprises: placing said blood product in a solid state in a closeable treating zone in the presence of a hydroxyl group-containing compound selected from the group consisting of water, methanol, ethanol, and mixtures thereof, and closing said treating zone; maintaining the content of said hydroxyl group-containing compound in said treating zone to provide said blood product with a content of hydroxyl group-containing compound of more than 0.05 (5% by weight) and less than 0.40 (40% by weight); and heating said blood product in the solid state in the closed treating zone at a temperature of between 50° and 121° C. to increase the partial vapor pressure of said hydroxyl group-containing compound, to thereby inactivate viable filterable pathogens.
Claim 22
Dependent Claim
158 words
A blood product, selected from the group consisting of enzymes, proenzymes, enzyme inhibitors, immunoglobulins, albumin, plasminogen, fibrinogen, fibronectin and plasma, produced by fractionation, wherein the blood product has been treated, at any desired stage of the fractionation, by a method which comprises: placing said blood product in a solid state in a closeable treating zone in the presence of a hydroxyl group-containing compound selected from the group consisting of water, methanol, ethanol, and mixtures thereof, and closing said treating zone; maintaining the content of said hydroxyl group-containing compound in said treating zone to provide said blood product with a content of hydroxyl group-containing compound of more than 0.05 (5% by weight) and less than 0.40 (40% by weight); and heating said blood product in the solid state in the closed treating zone at a temperature of between 50° and 121° C. to increase the partial vapor pressure of said hydroxyl group-containing compound, to thereby inactivate viable filterable pathogens.
Claim 23
Dependent Claim
14 words
A composition comprising the blood product of claim 19 in a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4160025A
Cited
EP0015055A1
Cited
US4388232A
Cited
DE2916711A1
Cited
EP0035204A2
Cited
US4440679A
Cited
US4395396A
Cited
EP0052827A2
Cited
EP0053338A2
Cited
US4424206A
Cited
WO1982003871A1
Cited
EP0077870A2
Cited
US4446134A
Cited
US4481189A
Cited
EP0094611A2
Cited
US4379085A
Cited
WO1983004371A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-02-02 | 1990-08-04 | 1991-02-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-02-02 | 1994-08-04 | 1995-02-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-02-02 | 1998-08-04 | 1999-02-03 | $7700.00 | Window Closed / Lapsed |